Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...

Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...

A study published in The Lancet showed a significant survival benefit for patients with oropharyngeal cancers who were ...

Sydney-based Immutep and Dr Reddy’s Laboratories have inked an exclusive licensing agreement through their arms for the ...

Immutep has landed a major offshore commercialisation deal worth $30m upfront and as much as $530 million in milestone ...

Zydus Life noted that population-scale studies show high rates of bone involvement, affecting 50-70% of advanced breast or ...

Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, ...

Keytruda plus platinum-based chemotherapy was found to be both safe and efficacious in treating penile squamous cell carcinoma (PSCC), according to findings from the phase 2 HERCULES trial presented ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has advised Intas ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

The S&P/ASX 300 Index (ASX: XKO) is getting plenty of help from this surging ASX 300 healthcare share today. Here’s why.